Difference between revisions of "Ceritinib (Zykadia)"
m (Text replacement - "[[File:" to "[[:File:") |
m |
||
| Line 17: | Line 17: | ||
*4/29/2014: [https://web.archive.org/web/20170213201352/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm395299.htm Accelerated approval] for the treatment of patients with [[Biomarkers#ALK|anaplastic lymphoma kinase (ALK)]]-[[Biomarkers#Rearrangement|positive]] metastatic [[Non-small_cell_lung_cancer|non-small cell lung cancer (NSCLC)]] who have progressed on or are intolerant to [[Crizotinib (Xalkori) | crizotinib]]. ''(Based on [https://clinicaltrials.gov/ct2/show/NCT01283516 ASCEND-1])'' | *4/29/2014: [https://web.archive.org/web/20170213201352/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm395299.htm Accelerated approval] for the treatment of patients with [[Biomarkers#ALK|anaplastic lymphoma kinase (ALK)]]-[[Biomarkers#Rearrangement|positive]] metastatic [[Non-small_cell_lung_cancer|non-small cell lung cancer (NSCLC)]] who have progressed on or are intolerant to [[Crizotinib (Xalkori) | crizotinib]]. ''(Based on [https://clinicaltrials.gov/ct2/show/NCT01283516 ASCEND-1])'' | ||
*5/26/2017: [https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560873.htm Granted regular FDA approval] for patients with metastatic [[Non-small_cell_lung_cancer|non-small cell lung cancer (NSCLC)]] whose tumors are [[Biomarkers#ALK|anaplastic lymphoma kinase (ALK)]]-[[Biomarkers#Rearrangement|positive]] as detected by an FDA-approved test. ''(Based on [https://clinicaltrials.gov/ct2/show/NCT01828099 ASCEND-4])'' | *5/26/2017: [https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560873.htm Granted regular FDA approval] for patients with metastatic [[Non-small_cell_lung_cancer|non-small cell lung cancer (NSCLC)]] whose tumors are [[Biomarkers#ALK|anaplastic lymphoma kinase (ALK)]]-[[Biomarkers#Rearrangement|positive]] as detected by an FDA-approved test. ''(Based on [https://clinicaltrials.gov/ct2/show/NCT01828099 ASCEND-4])'' | ||
| + | |||
| + | ==History of changes in EMA indication== | ||
| + | *5/6/2015: Initial marketing authorization as Zykadia. | ||
==Also known as== | ==Also known as== | ||
| Line 36: | Line 39: | ||
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] | ||
| + | [[Category:EMA approved in 2015]] | ||
[[Category:FDA approved in 2014]] | [[Category:FDA approved in 2014]] | ||
Revision as of 02:24, 5 December 2021
General information
Class/mechanism: Tyrosine kinase inhibitor; inhibits anaplastic lymphoma kinase (ALK). Ceritinib prevents growth of ALK-rearranged cancer cells by inhibiting autophosphorylation of ALK and subsequent ALK-mediated phosphorylation of the downstream signaling protein STAT3. In vitro, ceritinib is 20 times as potent against ALK as compared to Crizotinib (Xalkori) and inhibits growth of cells expressing EML4-ALK and NPM-ALK fusion proteins. Ceritinib has been observed in EML4-ALK-rearranged non-small cell lung cancer xenograft models to have activity against crizotinib-sensitive and crizotinib-resistant tumors. Ceritinib also inhibits the insulin-like growth factor 1 receptor (IGF-1R), insulin receptor (InsR), and ROS1. It does not inhibit MET.[1][2][3][4]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Ceritinib (Zykadia) package insert[1]
- Ceritinib (Zykadia) patient drug information (Chemocare)[5]
- Ceritinib (Zykadia) patient drug information (UpToDate)[6]
History of changes in FDA indication
- 4/29/2014: Accelerated approval for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. (Based on ASCEND-1)
- 5/26/2017: Granted regular FDA approval for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Based on ASCEND-4)
History of changes in EMA indication
- 5/6/2015: Initial marketing authorization as Zykadia.
Also known as
- Code name: LDK378
- Brand names: Lucicer, Noxalk, Spexib, Zykadia
References
- ↑ 1.0 1.1 1.2 Ceritinib (Zykadia) package insert
- ↑ Ceritinib (Zykadia) package insert (locally hosted backup)
- ↑ Zykadia manufacturer's website
- ↑ Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Lau YY, Goldwasser M, Boral AL, Engelman JA. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014 Mar 27;370(13):1189-97. link to original article PubMed
- ↑ Ceritinib (Zykadia) patient drug information (Chemocare)
- ↑ Ceritinib (Zykadia) patient drug information (UpToDate)